Targeting TAM to Tame Pancreatic Cancer

Mitchell S. von Itzstein, Michael C. Burke, Rolf A. Brekken, Todd A. Aguilera, Herbert J. Zeh, Muhammad Shaalan Beg

Research output: Contribution to journalReview articlepeer-review

Abstract

Pancreatic cancer is expected to become the second leading cause of cancer-related death within the next few years. Current therapeutic strategies have limited effectiveness and therefore there is an urgency to develop novel effective therapies. The receptor tyrosine kinase subfamily TAM (Tyro3, Axl, MerTK) is directly implicated in the pathogenesis of the metastatic, chemoresistant, and immunosuppressive phenotype in pancreatic cancer. TAM inhibitors are promising investigational therapies for pancreatic cancer due to their potential to target multiple aspects of pancreatic cancer biology. Specifically, recent mechanistic investigations and therapeutic combinations in the preclinical setting suggest that TAM inhibition with chemotherapy, targeted therapy, and immunotherapy should be evaluated clinically.

Original languageEnglish (US)
Pages (from-to)579-588
Number of pages10
JournalTargeted Oncology
Volume15
Issue number5
DOIs
StatePublished - Oct 1 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Targeting TAM to Tame Pancreatic Cancer'. Together they form a unique fingerprint.

Cite this